Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecamylamine challenge reversal study with galantamine and nicotine in healthy volunteers
NL-OMON42052Active, not recruiting
- Sponsor
- Centre for Human Drug Research
- Start
- Jul 2015
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of mecamylamine, galantamine and nicotine in Alzheimer's disease (AD) (4 arms), sponsored by Centre for Human Drug Research. Primary endpoints: Adaptive tracking, Pharmaco-EEG and 8 more. Started Jul 2015; status: active, not recruiting.
02
Drugs
mecamylaminegalantaminenicotine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON42052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42052.